JP2022526176A5 - - Google Patents

Info

Publication number
JP2022526176A5
JP2022526176A5 JP2021557760A JP2021557760A JP2022526176A5 JP 2022526176 A5 JP2022526176 A5 JP 2022526176A5 JP 2021557760 A JP2021557760 A JP 2021557760A JP 2021557760 A JP2021557760 A JP 2021557760A JP 2022526176 A5 JP2022526176 A5 JP 2022526176A5
Authority
JP
Japan
Prior art keywords
independently selected
pharmaceutically acceptable
substituted
acceptable salt
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021557760A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022526176A (ja
Filing date
Publication date
Priority claimed from GBGB1904374.4A external-priority patent/GB201904374D0/en
Application filed filed Critical
Publication of JP2022526176A publication Critical patent/JP2022526176A/ja
Publication of JP2022526176A5 publication Critical patent/JP2022526176A5/ja
Pending legal-status Critical Current

Links

JP2021557760A 2019-03-29 2020-03-24 炎症性障害の治療のための新規化合物及びその医薬組成物 Pending JP2022526176A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1904374.4A GB201904374D0 (en) 2019-03-29 2019-03-29 Novel compunds and pharmaceutical composistions thereof for the treatment of inflammatory disorders
GB1904374.4 2019-03-29
PCT/EP2020/058063 WO2020200899A1 (en) 2019-03-29 2020-03-24 Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Publications (2)

Publication Number Publication Date
JP2022526176A JP2022526176A (ja) 2022-05-23
JP2022526176A5 true JP2022526176A5 (cg-RX-API-DMAC7.html) 2023-04-04

Family

ID=66443107

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021557760A Pending JP2022526176A (ja) 2019-03-29 2020-03-24 炎症性障害の治療のための新規化合物及びその医薬組成物

Country Status (14)

Country Link
US (1) US20220194938A1 (cg-RX-API-DMAC7.html)
EP (1) EP3947377A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022526176A (cg-RX-API-DMAC7.html)
KR (1) KR20210143904A (cg-RX-API-DMAC7.html)
CN (1) CN113677679A (cg-RX-API-DMAC7.html)
AU (1) AU2020254882A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021019110A2 (cg-RX-API-DMAC7.html)
CA (1) CA3134735A1 (cg-RX-API-DMAC7.html)
GB (1) GB201904374D0 (cg-RX-API-DMAC7.html)
IL (1) IL286685A (cg-RX-API-DMAC7.html)
MX (1) MX2021011575A (cg-RX-API-DMAC7.html)
PH (1) PH12021552376A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202110678UA (cg-RX-API-DMAC7.html)
WO (1) WO2020200899A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201904373D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compounds and pharamaceutical compositions thereof for the treatment of inflammatory disorders
GB201904375D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders
WO2023098857A1 (zh) * 2021-12-03 2023-06-08 武汉人福创新药物研发中心有限公司 Irak4抑制剂及其用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005016928A1 (ja) * 2003-08-15 2005-02-24 Banyu Pharmaceutical Co., Ltd. イミダゾピリジン誘導体
US7566781B2 (en) * 2004-05-10 2009-07-28 Banyu Pharmaceutical Co., Ltd. Imidazopyridine compound
CA2992406A1 (en) * 2015-07-15 2017-01-19 Aurigene Discovery Technologies Limited Indazole and azaindazole compounds as irak-4 inhibitors
WO2017207386A1 (de) * 2016-06-01 2017-12-07 Bayer Pharma Aktiengesellschaft Verwendung von 2-substituierten indazolen zur behandlung und prophylaxe von autoimmunerkrankungen
WO2018060174A1 (de) * 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft Substituierte benzimidazole, pharmazeutische präparate diese enthaltend, sowie deren verwendung zur herstellung von arzneimitteln
WO2018060072A1 (de) * 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft Neue substituierte benzimidazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln
CN110835338A (zh) * 2018-08-17 2020-02-25 浙江海正药业股份有限公司 咪唑并吡啶类衍生物及其制备方法和其在医药上的用途
JP7576552B2 (ja) * 2019-01-18 2024-10-31 バイオジェン・エムエイ・インコーポレイテッド イミダゾ[1,2-a]ピリジニル誘導体及び疾患の処置におけるその使用
GB201904373D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compounds and pharamaceutical compositions thereof for the treatment of inflammatory disorders
GB201904375D0 (en) * 2019-03-29 2019-05-15 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Similar Documents

Publication Publication Date Title
JP2022526364A5 (cg-RX-API-DMAC7.html)
JP4495456B2 (ja) 新規の抗炎症性アンドロスタン誘導体
KR101064787B1 (ko) 아민 유도체
US8822439B2 (en) Glucocorticoid receptor agonists
ES2307751T3 (es) Nuevos esteres heterociclicos centi-inflamatorios 17 alfa de derivados 17 beta de carbotioato de androstano.
JP4471842B2 (ja) アミド化合物および該化合物を用いる方法
CN102770415B (zh) 作为溶血磷脂酸受体拮抗剂的多环化合物
EA020374B1 (ru) Производные бензолсульфонамида, фармацевтические композиции на их основе и применение
JP2018513180A5 (cg-RX-API-DMAC7.html)
US20100303758A1 (en) Novel Glucocorticoid Receptor Agonists
JP5897186B2 (ja) Pgds阻害剤としてのフェニルオキサジアゾール誘導体
ES2314395T3 (es) Derivados de (2-hidroxi-2-(4-hidroxi-3-hidroximetilfenil)-etilamino)-propil)fenilo como agonistas beta 2.
CA2867527A1 (en) Novel ep2 receptor agonists
JP2007529499A (ja) β2受容体アゴニストとしてのフェニルアミノエタノール誘導体
US8993568B2 (en) Morpholinyl derivatives useful as MOGAT-2 inhibitors
BRPI0619260A2 (pt) derivados de oxadiazol com atividade de receptor ctrh2, composição farmacêutica que os compreende e uso dos referidos derivados
WO2015008229A1 (en) Autotaxin inhibitors
JP4754829B2 (ja) 抗コリン作用を有するカルバミン酸エステル
KR20100047333A (ko) 아세트아미드 입체이성체
EP0074861B1 (en) Aminocyclopentane esters and their preparation and pharmaceutical formulation
JP4589006B2 (ja) ムスカリン様m3受容体の拮抗薬としてのヒドロキシ置換窒素複素環の新規エステル、その調製法並びに製薬組成物としてのその使用
US20170044208A1 (en) Selective glucocorticoid receptor ligands
CN102388025A (zh) 用作p38mapk抑制剂的嘧啶并哒嗪衍生物
JPWO2006118268A1 (ja) 慢性閉塞性肺疾患治療剤
JP2009507815A (ja) チアゾール化合物およびpgd2アンタゴニストとしてのその使用